ArticleIranian journal of medical sciences2018
Medullary Breast Carcinoma and Invasive Ductal Carcinoma: A Review Study.
Article in Iranian journal of medical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Survival outcomes by molecular subtypes based on receptor status in medullary breast carcinoma: a SEER database analysis.Translational cancer research · 2026Article
- FN1 as a key gene in modulating the integrin cell surface pathway in breast cancer.Medical oncology (Northwood, London, England) · 2026Article
- Clinical and pathological indicators for predicting disease-free survival after radical surgery in elderly patients with early-stage triple-negative invasive ductal carcinoma of the breast.Frontiers in oncology · 2026Article
- A population-based analysis of a risk stratification system for predicting radiotherapy benefits in invasive breast carcinoma of no special type with medullary pattern.European journal of medical research · 2025Article
- Medullary breast cancer and germline BRCA1 mutations: a possible criterion for genetic testing.Hereditary cancer in clinical practice · 2025Review
- Article
- Clinicopathological observation and prognostic factors of invasive breast cancer with medullary in Xinjiang.BMC medical informatics and decision making · 2025Article
- A comprehensive epidemiological analysis of breast cancer in the Eastern Province of Saudi Arabia.Scientific reports · 2025Article
- Iron chelators in breast cancer therapy: mechanisms and clinical applications - a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Envisioning Clinical Management of Breast Cancer: a Comprehensive Review.Current drug discovery technologies · 2025Review
- Prevalence and Predictors of Triple-Negative Breast Cancer Among Sudanese Women: A Retrospective Analysis of Newly Diagnosed Cases.International journal of women's health · 2025Article
- Comparison of the prognosis of medullary breast carcinoma and invasive ductal carcinoma: a SEER-based study.Translational cancer research · 2024Article
- Comparative study of microscale and macroscale technique for encapsulation of Calotropis gigantea extract in metal-conjugated nanomatrices for invasive ductal carcinoma.Scientific reports · 2023Article
- Recognizing invasive breast carcinoma of no special type with medullary pattern.Radiology case reports · 2023Article
- The 5-Year Disease-Free Survival of Third Generation Aromatase Inhibitor for Postmenopausal Women with HR-Positive HER2-Negative Non-Metastatic Breast Cancer.International journal of hematology-oncology and stem cell research · 2023Article
- Medullary breast cancer is a predominantly triple-negative breast cancer - histopathological analysis and comparison with invasive ductal breast cancer.Archives of medical science : AMS · 2022Article
- Effect of miRNA-136-targeted regulation of FGFR1 on proliferation and apoptosis of triple-negative breast cancer cells.American journal of translational research · 2021Article
- Hormone Receptor Status May Impact the Survival Benefit Between Medullary Breast Carcinoma and Atypical Medullary Carcinoma of the Breast: A Population-Based Study.Frontiers in oncology · 2021Article
- A comparison of breast cancer survival across different age groups: a multicentric database study in Penang, Malaysia.Epidemiology and health · 2021Article
- Inflammation, immunosuppressive microenvironment and breast cancer: opportunities for cancer prevention and therapy.Annals of translational medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedullary breast carcinoma (MBC) is a unique histological subtype of breast cancer. The present study aimed to evaluate the classic and non-classic characteristics of MBC and its differences with IDC. The present review study incorporates 22 years of practical experience from a breast disease research center-based series of cases.
methodsRetrospectively, the medical records of 3,246 patients were reviewed in the Breast Disease Research Center, Shiraz University of Medical Science (Shiraz, Iran), from December 1993 to December 2015. The tumor size, lymph node metastasis, pathologic stage, nuclear and histological grade, hormonal receptor status, recurrence, disease-free, and overall survival were reviewed. Differences between medullary breast carcinoma and invasive ductal carcinoma were analyzed statistically using the Chi-square, Fischer, independent-sample
resultsA total of 179 patients were identified with MBC and 3,067 patients were identified with IDC. The MBC group had a significant association with a higher histological grade (P<0.001) as well as negative estrogen receptor (P<0.001), progesterone receptor (P<0.001), and HER-2 (P=0.004) status. The MBC patients predominantly had triple-negative breast cancer (TNBC) according to the molecular subtype (P<0.001). In local invasion, MBC was less invasive compared to IDC (P<0.001). The disease-free survival (DFS) and overall survival (OS) differed significantly between the MBC and IDC groups (5-year DFS: 94.2% vs. 86.3%, P=0.008; 5-year OS: 98.1% vs. 92.8%, P=0.004).
conclusionDespite the poor and aggressive pathological features of MBC, its clinical outcome is more favorable compared to IDC. Our findings can be useful in improvement of diagnosis and treatment of less known breast cancer subtypes, such as MBC.
Indexed as
Identifiers
30046204PMC6055214What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.